



## LIST OF REFERENCES CITED

Attorney Docket No.  
R0145B-REGSerial No.  
10/634,936

Applicants

Goldstein, et al.

Filing Date  
August 5, 2003Group  
1614

## U.S. PATENT DOCUMENTS

Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date
con	A-1	4,215,216	29-Jul-1980	Scotese, et al.		
	A-2	5,037,826	06-Aug-1991	Blythin, et al.		
	A-3	5,620,981	15-Apr-1997	Blankley, et al.		
	A-4	5,733,913	31-Mar-1998	Blankley, et al.		
con	A-5	5,945,422	31-Aug-1999	Doherty, et al.		

## FOREIGN PATENT DOCUMENTS

	Ref. #	Document #	Date	Country; Assignee	Translation	
					Yes	No
con	B-1	WO 93/17682	16-Sep-1993	PCT; Abbott Laboratories		
	B-2	WO 99/61444	02-Dec-1999	PCT; Warner-Lambert Co.		
	B-3	WO 98/33798	06-Aug-1998	PCT; Warner-Lambert Co.		
	B-4	WO 96/34867	07-Nov-1996	PCT; Warner Lambert Co.		
	B-5	EP 0 278 686 A1	17-Aug-1988	European; The Wellcome Foundation Ltd.		
con	B-6	EP 0 790 997 B1	22-Mar-2000	European; Warner-Lamber Co.		

EXAMINER

DATE CONSIDERED


2/7/03


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED					Attorney Docket No. R0145B-REG	Serial No. 10/634,936	
					Applicants Goldstein, et al.		
					Filing Date August 5, 2003		Group 1614
U.S. PATENT DOCUMENTS							
Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date	
con	A-1	4,215,216	29-Jul-1980	Scotese, et al.			
	A-2	5,037,826	06-Aug-1991	Blythin, et al.			
	A-3	5,620,981	15-Apr-1997	Blankley, et al.			
	A-4	5,733,913	31-Mar-1998	Blankley, et al.			
	A-5	5,945,422	31-Aug-1999	Doherty, et al.			
FOREIGN PATENT DOCUMENTS							
	Ref.#	Document #	Date	Country; Assignee	Translation		
					Yes	No	
con	B-1	WO 93/17682	16-Sep-1993	PCT; Abbott Laboratories			
	B-2	WO 99/61444	02-Dec-1999	PCT; Warner-Lambert Co.			
	B-3	WO 98/33798	06-Aug-1998	PCT; Warner-Lambert Co.			
	B-4	WO 96/34867	07-Nov-1996	PCT; Warner Lambert Co.			
	B-5	EP 0 278 686 A1	17-Aug-1988	European; The Wellcome Foundation Ltd.			
con	B-6	EP 0 790 997 B1	22-Mar-2000	European; Warner-Lamber Co.			
EXAMINER <i>mwsaidp</i>				DATE CONSIDERED <i>2/7/05</i>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



LIST OF REFERENCE(S) CITED		Attorney Docket No. R0145B-REG	Serial No. 10/634,936
		Applicants Goldstein, et al.	
		Filing Date August 5, 2003	Group 1614
OTHER DOCUMENTS			
con	C-1	BOSCHELLI, et al, "Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines. Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors," <u>Journal of Med. Chem.</u> , (1998), pp 4365-4377, Vol. 41,	
	C-2	KLUTCHKO, et al., "2-Substituted Aminopyrido[2,3-d] pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and In Vitro and in Vivo Anticancer Activity," <u>Journal of Med. Chem.</u> , (1998), pp 3276-3292, Vol. 41	
	C-3	BARVIAN, et al., "Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases," <u>Journal of Med. Chem.</u> , (2000), pp 4606-4616, Vol. 43	
	C-4	HAMBY, et al., "Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors," <u>Journal Med. Chem.</u> , (1997), pp 2296-2303, Vol. 40	
	C-5	BOEHM and ADAMS, "New inhibitors of p38 kinase," <u>Expert Opinion on Therapeutic Patents</u> , Vol 10:1 (2000), pp 25-37	
	C-6	TRUMPP-KALLMEYER, et al., "Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors, <u>J. Medicinal Chemistry</u> , Vol. 41 (1998), pp 1752-1763	
EXAMINER- 		DATE CONSIDERED 2/7/05	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



LIST OF REFERENCE(S) CITED		Attorney Docket No. R0145B-REG	Serial No. 10/634,936
		Applicants Goldstein, et al.	
		Filing Date August 5, 2003	Group 1614
OTHER DOCUMENTS			
C-1 C-2 C-3 C-4 C-5 C-6	C-1	BOSCHELLI, et al, "Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines. Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors," <u>Journal of Med. Chem.</u> , (1998), pp 4365-4377, Vol. 41,	
	C-2	KLUTCHKO, et al., "2-Substituted Aminopyrido[2,3-d] pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity," <u>Journal of Med. Chem.</u> , (1998), pp 3276-3292, Vol. 41	
	C-3	BARVIAN, et al., "Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases," <u>Journal of Med. Chem.</u> , (2000), pp 4606-4616, Vol. 43	
	C-4	HAMBY, et al., "Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors," <u>Journal Med. Chem.</u> , (1997), pp 2296-2303, Vol. 40	
	C-5	BOEHM and ADAMS, "New inhibitors of p38 kinase," <u>Expert Opinion on Therapeutic Patents</u> , Vol 10:1 (2000), pp 25-37	
	C-6	TRUMPP-KALLMEYER, et al., "Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors, <u>J. Medicinal Chemistry</u> , Vol. 41 (1998), pp 1752-1763	
EXAMINER~ 		DATE CONSIDERED 2/7/05	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			